Clinical Trials

NCT IdNCT04833894
TitleEvaluating the Pharmacokinetics, Pharmacodynamics, and Safety of Efgartigimod Administered Intravenously in Children With Generalized Myasthenia Gravis
ConditionGeneralized Myasthenia Gravis
StudyTypeInterventional
Organizationargenx
Sponsor/Collaboratorsargenx
StatusNot yet recruiting
GenderAll
AgeGroupChild
Adult
Location (with distance)
DescriptionThe purpose of this trial is to investigate the PK, PD, safety, and activity of efgartigimod IV in children from 2 to less than 18 years of age with gMG. Trial details include: The maximum trial duration for each individual participant will be approximately 28 weeks The treatment duration will be 8 weeks for the dose-confirmatory part (Part A) and 18 weeks for the treatment response-confirmatory part (Part B)